What does SINOPHARMA do?

SINOPHARMA is a shop in Mouscron. Private Limited, started on 26 October 2015, 1 establishment.

What is the address of SINOPHARMA?

The registered office of SINOPHARMA is located at Haardstraat 59, 7700 Mouscron.

Is SINOPHARMA still active?

Yes. According to the CBE (31 October 2026) SINOPHARMA is active, legal situation “Normale toestand”, started on 26 October 2015.

Is SINOPHARMA registered on Peppol?

Yes, SINOPHARMA is registered on the Peppol network with ID 0208:0641889877.

What is the enterprise number of SINOPHARMA?

The enterprise number of SINOPHARMA is BE0641889877.

When was SINOPHARMA founded?

SINOPHARMA was founded on 26 October 2015.

Who are the directors of SINOPHARMA?

According to the 2025 annual accounts, the directors of SINOPHARMA are: RICHARD ZAGORSKI.

Is SINOPHARMA a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 26 October 2015; 5 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did SINOPHARMA make in 2025?

SINOPHARMA posted a profit after taxes of € 3,218 in financial year 2025.

What is the revenue of SINOPHARMA?

As a small company, SINOPHARMA is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 12,237.

SINOPHARMA (Private Limited) - Mouscron - BE0641889877

Dossier SINOPHARMA, printed on 31 October 2026 from databakkes.be/en/0641889877/sinopharma. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Busy address KBO

25 other companies have their registered office at the same address; threshold 10.

Financials

Financial year 2025

SINOPHARMA from Mouscron, company number BE0641889877, closed financial year 2025 with a result of € 3,218 after tax. For that financial year SINOPHARMA recorded a gross margin of € 12,237 and equity of € 12,765. Compared with financial year 2024, the result moved from € -11,629 to € 3,218. Profitable, and profit is growing. The buffer is growing. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on August 5, 2026.

What it is worth Growing

€ 12,765

▲ 34% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 3,218

▲ still € 11,629 loss in 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 3,118

▼ 82% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Growing

Stays in the company

No dividend for 2025. Retained profit grew to € -5,835.

People and assets in 2025

Full-time equivalents estimate The annual accounts report no full-time equivalents. A micro company with one active director is usually run by that person; this is an assumption, not a figure from the source.

≈ 1

No payroll staff. One director, so that person most likely runs the business.

Debts at end 2025

Bank debt

None

No bank loans on the last day of the fiscal year.

Owed to suppliers

€ 16,617

▼ 29% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes

€ 9,524

▼ 29% vs 2024

Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 31,200 Gross margin 2022: € 31,200 First fiscal year in the series	€ 11,313 Gross margin 2023: € 11,313 ▼ 64% vs 2022 (€ 31,200) Unfavourable step	€ -5,226 Gross margin 2024: € -5,226 ▼ € 16,540 vs 2023 (€ 11,313) Unfavourable step	€ 12,237 Gross margin 2025: € 12,237 ▲ € 17,463 vs 2024 (€ -5,226) Favourable step	▲ € 17,463
Profit after taxes	€ 14,659 Profit after taxes 2022: € 14,659 First fiscal year in the series	€ -1,510 Profit after taxes 2023: € -1,510 ▼ € 16,169 vs 2022 (€ 14,659) Unfavourable step	€ -11,629 Profit after taxes 2024: € -11,629 ▼ € 10,119 vs 2023 (€ -1,510) Unfavourable step	€ 3,218 Profit after taxes 2025: € 3,218 ▲ € 14,847 vs 2024 (€ -11,629) Favourable step	▲ € 14,847
Equity	€ 22,686 Equity 2022: € 22,686 First fiscal year in the series	€ 21,176 Equity 2023: € 21,176 ▼ 7% vs 2022 (€ 22,686) Unfavourable step	€ 9,547 Equity 2024: € 9,547 ▼ 55% vs 2023 (€ 21,176) Unfavourable step	€ 12,765 Equity 2025: € 12,765 ▲ 34% vs 2024 (€ 9,547) Favourable step	▲ 34%
Total debts	€ 56,596 Total debts 2022: € 56,596 First fiscal year in the series	€ 58,030 Total debts 2023: € 58,030 ▲ 3% vs 2022 (€ 56,596) Unfavourable step	€ 71,376 Total debts 2024: € 71,376 ▲ 23% vs 2023 (€ 58,030) Unfavourable step	€ 57,381 Total debts 2025: € 57,381 ▼ 20% vs 2024 (€ 71,376) Favourable step	▼ 20%
Cash	€ 31,351 Cash 2022: € 31,351 First fiscal year in the series	€ 16,448 Cash 2023: € 16,448 ▼ 48% vs 2022 (€ 31,351) Unfavourable step	€ 17,025 Cash 2024: € 17,025 ▲ 4% vs 2023 (€ 16,448) Favourable step	€ 3,118 Cash 2025: € 3,118 ▼ 82% vs 2024 (€ 17,025) Unfavourable step	▼ 82%
Retained profit	€ 4,086 Retained profit 2022: € 4,086 First fiscal year in the series	€ 2,576 Retained profit 2023: € 2,576 ▼ 37% vs 2022 (€ 4,086) Unfavourable step	€ -9,053 Retained profit 2024: € -9,053 ▼ € 11,629 vs 2023 (€ 2,576) Unfavourable step	€ -5,835 Retained profit 2025: € -5,835 ▲ € 3,218 vs 2024 (€ -9,053) Favourable step	▲ € 3,218
Dividend	€ 12,000 Dividend 2022: € 12,000 First fiscal year in the series	€ 0 Dividend 2023: € 0 ▼ 100% vs 2022 (€ 12,000) Unchanged	€ 0 Dividend 2024: € 0 Unchanged (€ 0) Unchanged	€ 0 Dividend 2025: € 0 Unchanged (€ 0) Unchanged
Balance sheet total	€ 79,282 Balance sheet total 2022: € 79,282 First fiscal year in the series	€ 79,205 Balance sheet total 2023: € 79,205 Unchanged (€ 79,282) Unchanged	€ 80,923 Balance sheet total 2024: € 80,923 ▲ 2% vs 2023 (€ 79,205) Unchanged	€ 70,146 Balance sheet total 2025: € 70,146 ▼ 13% vs 2024 (€ 80,923) Unchanged	▼ 13%

Key figures of SINOPHARMA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to SINOPHARMA?

What happened at SINOPHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Aug 5, 2026 New annual accounts for financial year 2025: profit of € 3,218. filed late Source: NBB ↗
Oct 26, 2015 New establishment in Mouscron. KBO
Oct 26, 2015 Start of the company according to the CBE. KBO

In short

From € 14,659 profit in 2022 to € 3,218 profit in 2025.

Paid € 18,595 in corporate taxes since 2022.

Best year ever: 2022, with € 14,659 profit.

Paid out € 12,000 in dividends to the owners in total.

Original PDFs at the National Bank ↗

Management

RICHARD ZAGORSKI

SINOPHARMA

Behind SINOPHARMA is RICHARD ZAGORSKI.

Directors

According to the 2025 annual accounts

RICHARD ZAGORSKI

administrateur

Establishments

Establishment units

Physical locations of this company

Registered office

Haardstraat 59

7700 Mouscron

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 25 companies are registered at this address.

All companies at this address →

SAMARKAND

€ -5,294 gross margin · 2025

EXON DISTRIBUTION

€ 2,871 gross margin · 2025

E.C. IMMO

€ 116,184 gross margin · 2025

DHAIMOND

€ 4,328 gross margin · 2024

FERVAILLE SRL

€ 1,720 gross margin · 2025

+20 more

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0641.889.877

VAT number

BE 0641.889.877

Registered office

Haardstraat 59, 7700 Mouscron

Names & denominations

SINOPHARMA

Enterprise type

Rechtspersoon

Legal form

Private limited company

Legal situation

Normale toestand

Start date

26 October 2015

Peppol

Active · Active since 15 Dec 2025

Activities · NACE

Detailhandel in medische en orthopedische artikelen, muv corrigerende brillen, lenzen en zonnebrillen

Detailhandel in medische en orthopedische artikelen in gespecialiseerde winkels

Detailhandel in drogisterijartikelen en onderhoudsproducten

Groothandel in parfumerieën en cosmetica

Detailhandel in drogisterijartikelen en onderhoudsproducten in gespecialiseerde winkels

View on CBE Public ↗ Annual accounts (NBB) ↗

SINOPHARMA

Warning lights

Financials

What happened to SINOPHARMA?

Management

Directors

Establishments

Establishment units

Who else lives here?

Details

Frequently asked questions